Other therapy.

Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial

PUBLICATION: Acta Medica Academica. Volume 48 (2) August 2019 AUTHOR: Read More

2024-03-25T08:46:25-04:00August 2nd, 2019|Adjuvant, Evidence, MammaPrint, MINDACT, Other, Validation|

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Read More

2024-03-25T08:56:28-04:00March 27th, 2019|BluePrint, Evidence, Other, Validation|

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Read More

2024-03-27T10:20:24-04:00April 18th, 2018|BluePrint, Evidence, HER2-positive, I-SPY2, Neoadjuvant, Other|

Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients

PUBLICATION: J Breast Cancer. 2017 Sep;20(3):246-253. English. Published online Sep Read More

2024-03-25T09:00:19-04:00September 22nd, 2017|BluePrint, Evidence, MammaPrint, Other, Validation|

Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.

PUBLICATION: Breast Cancer Res Treat (2016) 159: 481. https://doi.org/10.1007/s10549-016-3949-y09. AUTHORS: Read More

2024-03-25T09:17:41-04:00August 27th, 2016|Evidence, MammaPrint, Other, Racial Disparities|

Breast Cancer: Determining the Genetic Profile from Ultrasound-Guided Percutaneous Biopsy Specimens Obtained During Diagnostic Workups

PUBLICATION: Radiologรญa (English Edition) Volume 58, Issue 3, Mayโ€“June 2016, Read More

2024-03-25T09:20:15-04:00June 14th, 2016|Evidence, MammaPrint, Other|
Go to Top